The “Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East” surveyed 2,500 people. It featured individuals with type 2 diabetes and healthcare professionals across Germany, Italy, the Netherlands, Saudi Arabia, Spain and the UK.
Findings delivered insights into care and perceptions of diabetes technology within the type 2 population, according to a news release. Dexcom delivered this report to kick off the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam.
The State of Type 2 report serves as a call to action for policymakers, the company says. It demonstrates the benefits of continuous glucose monitor (CGM) technology for the significant amount of people with type 2 diabetes across the regions it surveyed.
A look at the findings from Dexcom’s survey around type 2 diabetes
Findings highlighted the significance of access to CGM and education. More than half (52%) of healthcare providers ranked access as having the potential to help people with type 2 manage their condition in the next 10 years. That compared to 38% who opted for better or more effective medications.
Dexcom said 77% of people with type 2 diabetes who hadn’t used CGM expected it to improve the lives of those with type 2. That compared to 93% of people with type 2 who used CGM and agreed it had a positive impact.
Healthcare providers see CGM as the standard of care, with 96% agreeing that those on multiple daily insulin injections should use CGM. Additionally, 86% agreed that those relying on basal insulin should be offered CGM. Providers see funding constraints (35%) and narrow inclusion criteria (20%) as the primary barriers to CGM adoption.
“With policymakers increasingly focused on digital transformation in healthcare, now is the time to push for greater investment in CGM technology as a core component of type 2 management,” said Adrian Gut, senior director of international access, advocacy and value at Dexcom. “Enhancing CGM accessibility is crucial to tackling the Type 2 crisis. By ensuring equitable access to this life-changing technology, we can empower people with type 2 to take control of their diabetes management, improve their quality of life and reduce complications. This will significantly improve public health outcomes and reduce long-term healthcare costs. Now is the time to make a transformative impact on the lives of millions.”
